No profile data available.
Aptevo Therapeutics Inc. (APVO) is a healthcare company in the blood cancer treatment drugs industry, based in Seattle, United States, with about 33 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$27.54 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $3.24 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Aptevo Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$3.24 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Karyopharm Therapeutics Inc. (KPTI), Cellectar Biosciences, Inc. (CLRB), IN8bio, Inc. (INAB), Alaunos Therapeutics, Inc. (TCRT).